117 related articles for article (PubMed ID: 38237390)
1. Second generation of pyrimidin-quinolone hybrids obtained from virtual screening acting as sphingosine kinase 1 inhibitors and potential anticancer agents.
Vettorazzi M; Díaz I; Angelina E; Salido S; Gutierrez L; Alvarez SE; Cobo J; Enriz RD
Bioorg Chem; 2024 Mar; 144():107112. PubMed ID: 38237390
[TBL] [Abstract][Full Text] [Related]
2. Identifying novel sphingosine kinase 1 inhibitors as therapeutics against breast cancer.
Khan FI; Lai D; Anwer R; Azim I; Khan MKA
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):172-186. PubMed ID: 31752564
[TBL] [Abstract][Full Text] [Related]
3. An integrative study to identify novel scaffolds for sphingosine kinase 1 inhibitors.
Vettorazzi M; Angelina E; Lima S; Gonec T; Otevrel J; Marvanova P; Padrtova T; Mokry P; Bobal P; Acosta LM; Palma A; Cobo J; Bobalova J; Csollei J; Malik I; Alvarez S; Spiegel S; Jampilek J; Enriz RD
Eur J Med Chem; 2017 Oct; 139():461-481. PubMed ID: 28822281
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and biological evaluation of novel benzimidazole derivatives as sphingosine kinase 1 inhibitor.
Khairat SHM; Omar MA; Ragab FAF; Roy S; Turab Naqvi AA; Abdelsamie AS; Hirsch AKH; Galal SA; Hassan MI; El Diwani HI
Arch Pharm (Weinheim); 2021 Sep; 354(9):e2100080. PubMed ID: 34128259
[TBL] [Abstract][Full Text] [Related]
5. Design of new quinolin-2-one-pyrimidine hybrids as sphingosine kinases inhibitors.
Vettorazzi M; Insuasty D; Lima S; Gutiérrez L; Nogueras M; Marchal A; Abonia R; Andújar S; Spiegel S; Cobo J; Enriz RD
Bioorg Chem; 2020 Jan; 94():103414. PubMed ID: 31757412
[TBL] [Abstract][Full Text] [Related]
6. PF543-like compound, a promising sphingosine kinase 1 inhibitor: Structure-based virtual screening and molecular dynamic simulation approaches.
Shahwan M; Hassan N; Ashames A; Alrouji M; Alhumaydhi F; Al Abdulmonem W; Muhsinah AB; Furkan M; Khan RH; Shamsi A; Atiya A
Int J Biol Macromol; 2023 Aug; 245():125466. PubMed ID: 37348582
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of ellagic acid as an inhibitor of sphingosine kinase 1: A targeted approach towards anticancer therapy.
Gupta P; Mohammad T; Khan P; Alajmi MF; Hussain A; Rehman MT; Hassan MI
Biomed Pharmacother; 2019 Oct; 118():109245. PubMed ID: 31352240
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, photophysical properties, anticancer evaluation, and molecular docking studies of new pyrimidine linked 4-arylidene-thiazolidin-4-ones as potent anticancer agents.
Jame R
Luminescence; 2024 Jan; 39(1):e4672. PubMed ID: 38286597
[TBL] [Abstract][Full Text] [Related]
9. Molecular Docking and In Vitro Anticancer Screening of Synthesized Arylthiazole linked 2H-indol-2-one Derivatives as VEGFR-2 Kinase Inhibitors.
Shalmali N; Bawa S; Ali MR; Kalra S; Kumar R; Zeya B; Rizvi MA; Partap S; Husain A
Anticancer Agents Med Chem; 2022; 22(11):2166-2180. PubMed ID: 34792005
[TBL] [Abstract][Full Text] [Related]
10. Design, Synthesis, biological Evaluation, and molecular docking studies of novel Pyrazolo[3,4-d]Pyrimidine derivative scaffolds as potent EGFR inhibitors and cell apoptosis inducers.
Sherbiny FF; Bayoumi AH; El-Morsy AM; Sobhy M; Hagras M
Bioorg Chem; 2021 Nov; 116():105325. PubMed ID: 34507234
[TBL] [Abstract][Full Text] [Related]
11. Discovering Gummadiol and Isoarboreol as potential inhibitors of sphingosine kinase 1: virtual screening and MD simulation studies.
Elasbali AM; Al-Soud WA; Alhassan HH; Mousa Elayyan AE; Kamal M; Alanazi H; Alharbi B; Alharethi SH; Mohamed BM
J Biomol Struct Dyn; 2023; 41(22):12789-12797. PubMed ID: 36644886
[TBL] [Abstract][Full Text] [Related]
12. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
[TBL] [Abstract][Full Text] [Related]
13. Utilization of cyanopyridine in design and synthesis of first-in-class anticancer dual acting PIM-1 kinase/HDAC inhibitors.
Bass AKA; Nageeb EM; El-Zoghbi MS; Mohamed MFA; Badr M; Abuo-Rahma GEA
Bioorg Chem; 2022 Feb; 119():105564. PubMed ID: 34959179
[TBL] [Abstract][Full Text] [Related]
14. Theoretical models to predict the inhibitory effect of ligands of sphingosine kinase 1 using QTAIM calculations and hydrogen bond dynamic propensity analysis.
Vettorazzi M; Menéndez C; Gutiérrez L; Andujar S; Appignanesi G; Enriz RD
J Comput Aided Mol Des; 2018 Jul; 32(7):781-791. PubMed ID: 29971548
[TBL] [Abstract][Full Text] [Related]
15. Discovery of New Quinolone-Based Diarylamides as Potent B-RAF
Kim HJ; Park JW; Seo S; Cho KH; Alanazi MM; Bang EK; Keum G; El-Damasy AK
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834628
[TBL] [Abstract][Full Text] [Related]
16. Structural optimization of 4-(imidazol-5-yl)pyridine derivatives affords broad-spectrum anticancer agents with selective B-RAF
Ali EMH; Mersal KI; Ammar UM; Zaraei SO; Abdel-Maksoud MS; El-Gamal MI; Haque MM; Das T; Kim EE; Lee JS; Lee KH; Kim HK; Oh CH
Eur J Pharm Sci; 2022 Apr; 171():106115. PubMed ID: 34995782
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, Molecular Docking and Biological Evaluation of Quinolone Derivatives as Novel Anticancer Agents.
Li J; Zheng TC; Jin Y; Xu JG; Yu JG; Lv YW
Chem Pharm Bull (Tokyo); 2018 Jan; 66(1):55-60. PubMed ID: 29118308
[TBL] [Abstract][Full Text] [Related]
18. New C2- and N3-Modified Thieno[2,3-d]Pyrimidine Conjugates with Cytotoxicity in the Nanomolar Range.
Mavrova AT; Dimov S; Yancheva D; Rangelov M; Wesselinova D; Naydenova E
Anticancer Agents Med Chem; 2022; 22(6):1201-1212. PubMed ID: 34315388
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological evaluation of 2-epi-jaspine B analogs as selective sphingosine kinase 1 inhibitors.
Yang H; Li Y; Chai H; Yakura T; Liu B; Yao Q
Bioorg Chem; 2020 May; 98():103369. PubMed ID: 31703810
[TBL] [Abstract][Full Text] [Related]
20. Structure-activity relationship studies and bioactivity evaluation of 1,2,3-triazole containing analogues as a selective sphingosine kinase-2 inhibitors.
Tangadanchu VKR; Jiang H; Yu Y; Graham TJA; Liu H; Rogers BE; Gropler R; Perlmutter J; Tu Z
Eur J Med Chem; 2020 Nov; 206():112713. PubMed ID: 32919113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
